Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Sali RCTsofosbuvirlopinavir/ritonavirCOVID 19 hospitalizedhigh
22/32 inconclusive
    Nojomi
          IRCT20180725040596N2    		 RCTumifenovir (arbidol)lopinavir/ritonavirCOVID 19 hospitalizedsome concern
    		50/50 inconclusive
      Nojomi
              IRCT20180725040596N2      		 RCTlopinavir/ritonavirumifenovir (arbidol)COVID 19 hospitalizedsome concern
      		50/50 inconclusive

        COVID 19 all comers meta-analysis

        Chang Chen et al.
                  ChiCTR2000030254        		 RCTfavipiravir umifenovir (arbidol)COVID 19 all comerssome concern
        		120/120 inconclusive
        • inconclusive 48 % increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
        jRCTs041190120
                  jRCTs041190120        		 RCTfavipiravir favipiravir COVID 19 all comershigh
        		44/45 inconclusive
        • inconclusive 42 % increase in viral clearance ,viral clearance (time to event analysis only) (PE) but with a low degree of certainty due to high risk of bias
        Calik OBSfavipiravir hydroxychloroquineCOVID 19 all comerscritical
        		-/- no results
          Cai -FAVIPIRAVIR
                      ChiCTR2000029600          		 NRafavipiravir lopinavir/ritonavirCOVID 19 all comersNA
          		35/45 uncontrolled
          • [uncontrolled] Chest CT improvement (day 14): 91.4% (32/35)

          COVID-19 mild to moderate meta-analysis

          Babalola RCTivermectinlopinavir/ritonavirCOVID-19 mild to moderatehigh
          		21/20 no results
            Solaymani-Dodaran
                          IRCT20200318046812N1            		 RCTfavipiravir lopinavir/ritonavirCOVID-19 mild to moderatesome concern
            		193/187 inconclusive
              ELACOI (Lopinavir/ritonavir)
                              NCT04252885              		 RCTumifenovir (arbidol)lopinavir/ritonavirCOVID-19 mild to moderatesome concern
              		35/34 inconclusive
              • inconclusive 84 % increase in viral clearance by day 14 (PE) with a moderate degree of certainty due to some concern in risk of bias
              • inconclusive 8 % increase in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
              GS-US-540-5773 (Goldman)
                              NCT04292899              		 RCTremdesivirremdesivirCOVID-19 mild to moderatesome concern
              		200/197 suggested
              • suggested 53 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
              Hung et al.
                              NCT04276688              		 RCTlopinavir/ritonavir, ribavirin and interferon beta-1blopinavir/ritonavirCOVID-19 mild to moderatesome concern
              		86/41 conclusif
              • demonstrated 3.4-fold increase in viral clearance ,viral clearance (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
              • suggested 2.9-fold increase in clinical improvement,clinical improvement (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
              Ren
                              ChiCTR2000029853              		 RCTazvudineantiviral and associated therapyCOVID-19 mild to moderatesome concern
              		10/10 suggested
              • suggested 27.5-fold increase in viral clearance ,viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias

              COVID-19 severe or critically meta-analysis

              Galan
                              RBR-8h7q82              		 RCTivermectinchloroquine and derivativesCOVID-19 severe or criticallysome concern
              		53/115 suggested
              • inconclusive 6 % decrease in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
              • suggested 86 % decrease in mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
              Galan
                              RBR-8h7q82              		 RCTivermectinhydroxychloroquineCOVID-19 severe or criticallysome concern
              		53/115 suggested
              • inconclusive 6 % decrease in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
              • suggested 86 % decrease in mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
              Kocayigit H OBSfavipiravir lopinavir/ritonavirCOVID-19 severe or criticallyNA
              		65/42 inconclusive
                Eslami
                                  IRCT20200324046850N2                		 NRasofosbuvir and daclatasvirribavirinCOVID-19 severe or criticallyNA
                		35/27 uncontrolled
                • [uncontrolled] deaths: 5.7% (2/35)
                • [uncontrolled] recovery rate: 94.3% (33/35)

                PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

                 

                - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons